Mobia Medical's Post-IPO Fade Is Down to One Floor: $10.20 Decides the Next Move

Mobia Medical went public at $15 in May, touched $15.29 within days, and has spent the months since giving the offering back. As of today's session it trades near $11.45 — down about 24% from the offer and barely above its 52-week low of $10.19. One floor now separates a base from a breakdown.

If you only read the fundamentals, this stock reads like a growth story that ran ahead of itself, not a broken one. Vivistim is an FDA-approved implantable device that Mobia says is the first and only approved implantable solution for this indication. Second-quarter revenue nearly doubled to $13.5 million, up 102%. The catch: the company still lost $21 million in the quarter, or $1.10 a share. Strong growth, no profit, and a stock trading a quarter below its IPO price. That gap is the whole trade right now.

The chart has one real floor — and only one

Because Mobia only went public on May 7, its public chart is young. The 52-week low of $10.19 is not just a number; it is the price floor the stock has ever traded at, since there is no meaningful history beneath the post-IPO range. That climbing frame is the last line before an air pocket: below $10.20, there is no tested support until a fresh low prints on a tape that barely trades.

Above the floor, the structure is symmetrical but lazy. The stock sits under its 50-day average, which sits near $11.90, and that average has been acting as resistance on the way down. The offers at $15 — the IPO line, where 10 million shares priced at $15 per share for roughly $150 million — and the $15.29 post-debut high loom overhead as a wall of trapped buyers looking to break even. Every bounce toward $12 or $13 has to chew through that inventory before any real upside opens.

The honest part: this is a bad price to chase

The reward-to-risk arithmetic argues against buying the current $11.45 print. The first resistance, the 50-day average near $11.90, is only about 4% away, while the level that would invalidate the setup, the $10.19 floor, sits roughly 11% below. Paying up here means a small payoff before the first wall and a long walk to your stop. That is the opposite of the asymmetry a technical setup should offer.

The setups worth waiting for are clearer at either edge:

Scenario	Trigger	Path	Invalidation	Horizon
Floor defense	A defended retest of the $10-ish zone with real volume	Grind back toward the $11.90 average, then the $13–15 offers overhead	Daily close below $10.19	Weeks
Reclaim	A close back above ~$12, reclaiming the 50-day average	Reopens the path toward the $15 IPO line	A rejection that slips back under $11	Days to weeks
Breakdown	$10.19 breaks on expanding volume	Air pocket; no tested support below the post-IPO low	—	Days

Who shows up, not what headlines say, decides it

The reason the floor matters is the tape is thin. Today's turnover is only a few hundred thousand dollars' worth of stock on fewer than 50,000 shares, and order-flow data shows the dip is being caught by retail-sized trades with no block-sized institutional bid appearing. The thin trade cuts both ways: it makes the $10 zone easy to crack on a bad print, but it also means a genuine burst of buying can snap the stock away from the lows quickly because there is little standing inventory to absorb a bid.

Everything now runs through $10.20. The stock defends that floor and the 102% revenue growth buys the chart time to build a base that eventually retests the IPO offers. Lose $10.19 on volume and the story stops being "young growth stock digesting" and becomes a fresh IPO distributing into a market that barely traded it in the first place. There is no middle ground at this price — just the floor, and whichever side of it the next few sessions land on.